RxDoctor Payments Data

Supreeti Behuria, MD

Cardiovascular Disease · Staten Island, NYNPI 1417240268

Payments from drug & device makers

$34,846in general payments, 2019–2025

Across 86 payments — averaging $405.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$34K
  • Gilead$125
  • AstraZeneca$125
  • Pfizer$124
  • Novartis$109
  • Boston Scientific$96
  • plus $22 from 1 others

What the payments were for

  • Consulting fees$16,15046%
  • Speaking & faculty fees$8,60025%
  • Travel & lodging$6,97720%
  • Food & beverage$3,1199%

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Medtronic79$34,245
Gilead1$125
AstraZeneca1$125
Pfizer1$124
Novartis2$109
Boston Scientific1$96
Johnson & Johnson1$22

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$34,846 in reported general payments places this provider in the 85th percentile of 2,302 cardiovascular disease providers in New York.

See all cardiovascular disease providers in New York

Medicare billing

Part B allowed, 2024
$164,138
Medicare patients
1,237
Services billed
2,313

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban41$46,687
EntrestoSacubitril/Valsartan26$30,213
FarxigaDapagliflozin Propanediol21$15,935
XareltoRivaroxaban15$11,822
Repatha SureclickEvolocumab21$11,433
Rosuvastatin Calcium92$1,826
Metoprolol Succinate129$1,621
Atorvastatin Calcium142$1,147
Nifedipine ErNifedipine53$856
Losartan Potassium84$853
Diltiazem 24hr Er (Cd)Diltiazem Hcl14$620
Ezetimibe35$385
Hydrochlorothiazide65$306
Amlodipine Besylate96$290
Isosorbide Mononitrate ErIsosorbide Mononitrate37$246

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$124$46,68741 claims
NovartisEntresto$109$30,21326 claims
AstraZenecaFarxiga$125$15,93521 claims
Johnson & JohnsonXarelto$22$11,82215 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,302 cardiovascular disease providers in New York.

Other cardiovascular disease in Staten Island

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →